These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8935859)

  • 1. [Mass screening for colorectal cancer].
    Faivre J; Tazi MA; Launoy G
    Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of various screening and surveillance methods in colorectal carcinoma].
    Burchert A; Schmassmann A
    Schweiz Med Wochenschr; 1998 Jun; 128(25):999-1011. PubMed ID: 9691335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening for colorectal cancer--does it help?].
    Kronborg O
    Nord Med; 1993; 108(10):256-8. PubMed ID: 8414943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of colorectal carcinoma. Annual hemoccult test and sigmoidoscopy every 5 years].
    Rosenbaum A; Riemann JF
    MMW Fortschr Med; 2000 Aug; 142(31-32):27-9. PubMed ID: 10992763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
    Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
    Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for rectal cancer.
    St John DJ
    Hepatogastroenterology; 2000; 47(32):305-9. PubMed ID: 10791177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiology and screening of colorectal cancer].
    Dancourt V; Faivre J
    Rev Prat; 2004 Jan; 54(2):135-42. PubMed ID: 15086055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
    Berry DP; Clarke P; Hardcastle JD; Vellacott KD
    Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Randomized controlled trial of sequence mass screening program for colorectal cancer].
    Liu X; Zheng S; Chen K; Ma X; Zhou L; Yu H; Yao K; Chen K; Cai S; Zhang S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):430-3. PubMed ID: 11860828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence-based planning: the case of mass screening for colorectal cancer in the Lazio region of Italy].
    Federici A; Borgia P; Guasticchi G
    Ann Ig; 2005; 17(4):313-22. PubMed ID: 16156391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost of a mass screening program for colorectal cancer using the occult blood test].
    Arveux P; Faivre J; Bedenne L; Durand G; Milan C; Milan C
    Gastroenterol Clin Biol; 1992; 16(6-7):547-51. PubMed ID: 1526416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.